Use of GLP-1 RAs is associated with reduced postoperative revision following functional endoscopic sinus surgery for up to 5 years among patients with chronic rhinosinusitis with nasal polyps and ...
PF'3944 is an ultra-long-acting fully biased GLP-1 receptor agonist (RA). It is being developed as a single agent weekly and as a monthly therapy, and in combination with various peptides including an ...
In a real-world study, patients with psoriatic disease treated with an IL-17 targeted biologic and a GLP-1 agonist ...
GLP-1RA use improves major cardiovascular and kidney outcomes among patients with systemic lupus erythematosus and lupus nephritis. Use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) is ...
Kayshild is recommended for adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis and ...
BEIJING, Nov. 27, 2025 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, stock code: 603087.SH) announced the initiation of GRADUAL-3, its third large-scale phase 3 clinical study of the ...
GLP-1 RA use was associated with significantly lower epilepsy risk, with protective associations seen at 1, 3, and 5 years. (HealthDay News) — For adults with type 2 diabetes mellitus (T2DM), glucagon ...
Association persisted after removing patients with previous diagnosis of gastroesophageal reflux. (HealthDay News) — For patients with type 2 diabetes, there is an association between glucagon-like ...
Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo COYA 303 is an investigational ...
GLP-1 receptor agonists tied to reduced acute asthma exacerbations in teens with overweight, obesity
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a lower risk for acute asthma exacerbations in adolescents with overweight or obesity, according to a research letter ...
US pharma giant Pfizer today announced positive top-line results from the Phase IIb VESPER-3 study investigating monthly ...
Those prescribed a GLP-1 RA had a significantly increased risk for new chronic cough compared with those prescribed any non-GLP-1 RA second-line medication, DPP-4 inhibitor, or sulfonylurea in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results